An exon 10 deletion in the mouse ferrochelatase gene has a dominant-negative effect and causes mild protoporphyria
- 15 August 2002
- journal article
- Published by American Society of Hematology in Blood
- Vol. 100 (4) , 1470-1477
- https://doi.org/10.1182/blood-2001-12-0283
Abstract
Protoporphyria is generally inherited as an autosomal dominant disorder. The enzymatic defect of protoporphyria is a deficiency in ferrochelatase, which chelates iron and protoporphyrin IX to form heme. Patients with protoporphyria have decreased ferrochelatase activities that range from 5% to 30% of normal caused by heterogeneous mutations in the ferrochelatase gene. The molecular mechanism by which the ferrochelatase activity is decreased to less than an expected 50% is unresolved. In this study, we assessed the effect of a ferrochelatase exon 10 deletion, a common mutation in human protoporphyria, introduced into the mouse by gene targeting. F1 crosses produced (+/+), (+/−), and (−/−) mice at a ratio of 1:2:0; (−/−) embryos were detected at 3.5 days postcoitus, consistent with embryonic lethality for the homozygous mutant genotype. Heterozygotes demonstrated equivalent levels of wild-type and mutant ferrochelatase messenger RNAs and 2 immunoreactive proteins that corresponded to the full-length and an exon 10–deleted ferrochelatase protein. Ferrochelatase activities in the heterozygotes were an average of 37% of normal, and protoporphyrin levels were elevated in erythrocytes and bile. Heterozygous mice exhibited skin photosensitivity but no liver disease. These results lend support for a dominant-negative effect of a mutant allele on ferrochelatase activity in patients with protoporphyria.Keywords
This publication has 53 references indexed in Scilit:
- Successful therapeutic effect in a mouse model of erythropoietic protoporphyria by partial genetic correction and fluorescence-based selection of hematopoietic cellsGene Therapy, 2001
- Reversion of hepatobiliary alterations by bone marrow transplantation in a murine model of erythropoietic protoporphyriaHepatology, 2000
- Follow-up after liver transplantation for protoporphyric liver diseaseLiver Transplantation and Surgery, 1996
- Ferrochelatase cDNA Delivered by Adenoviral Vector Corrects Biochemical Defect in Protoporphyric CellsHuman Gene Therapy, 1995
- Recessive inheritance of erythropoietic protoporphyria with liver failureThe Lancet, 1994
- A novel mutation in erythropoietic protoporphyria: an aberrant ferrochelatase mRNA caused by exon skipping during RNA splicingBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1993
- Human Erythropoietic Protoporphyria: Two point mutations in the ferrochelatase geneBiochemical and Biophysical Research Communications, 1991
- Spectroscopic examination of the active site of bovine ferrochelataseBiochemistry, 1985
- Mouse Model For Protoporphyria I. The Liver and Hepatic Protoporphyrin CrystalsJournal of Investigative Dermatology, 1975
- Hematopoiesis in the embryonic mouse spleen. II. Alterations after phenylhydrazine administration to the mothersThe Anatomical Record, 1975